FY2023 Earnings Estimate for Vir Biotechnology, Inc. (NASDAQ:VIR) Issued By HC Wainwright

Vir Biotechnology, Inc. (NASDAQ:VIR) – Analysts at HC Wainwright boosted their FY2023 EPS estimates for Vir Biotechnology in a note issued to investors on Tuesday, November 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($4.70) for the year, up from their previous forecast of ($4.98). HC Wainwright currently has a “Buy” rating and a $95.00 target price on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($4.81) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q4 2023 earnings at ($0.98) EPS, FY2024 earnings at ($4.42) EPS, FY2025 earnings at ($1.66) EPS, FY2026 earnings at ($0.95) EPS and FY2027 earnings at ($0.25) EPS.

Other research analysts have also issued research reports about the stock. Needham & Company LLC dropped their price objective on shares of Vir Biotechnology from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Bank of America lowered shares of Vir Biotechnology from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $23.00 to $14.00 in a research note on Friday, September 8th. The Goldman Sachs Group dropped their price objective on shares of Vir Biotechnology from $51.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, July 21st. Morgan Stanley dropped their price target on shares of Vir Biotechnology from $27.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Friday, July 21st. Finally, Barclays dropped their price target on shares of Vir Biotechnology from $59.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, July 21st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $36.33.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $8.14 on Thursday. The firm’s 50 day simple moving average is $9.24 and its 200-day simple moving average is $17.01. The company has a market cap of $1.10 billion, a P/E ratio of -4.13 and a beta of 0.31. Vir Biotechnology has a fifty-two week low of $7.72 and a fifty-two week high of $31.55.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently bought and sold shares of VIR. Rhumbline Advisers lifted its holdings in shares of Vir Biotechnology by 5.8% during the 3rd quarter. Rhumbline Advisers now owns 261,987 shares of the company’s stock worth $2,455,000 after acquiring an additional 14,374 shares during the period. Deutsche Bank AG lifted its holdings in shares of Vir Biotechnology by 14.0% during the 3rd quarter. Deutsche Bank AG now owns 42,476 shares of the company’s stock worth $398,000 after acquiring an additional 5,219 shares during the period. Citigroup Inc. lifted its holdings in shares of Vir Biotechnology by 64.5% during the 3rd quarter. Citigroup Inc. now owns 257,453 shares of the company’s stock worth $2,412,000 after acquiring an additional 100,975 shares during the period. Texas Permanent School Fund Corp lifted its holdings in shares of Vir Biotechnology by 7.9% during the 3rd quarter. Texas Permanent School Fund Corp now owns 72,525 shares of the company’s stock worth $680,000 after acquiring an additional 5,285 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Vir Biotechnology by 35.4% during the 3rd quarter. UBS Group AG now owns 285,532 shares of the company’s stock worth $2,675,000 after acquiring an additional 74,704 shares during the period. 67.05% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.